Table 5.

Poststudy treatment experience of patients with SD

Subject IDDiseaseALT-801 dose level (mg/kg)Time to progression (mo)aSurvival (mo)a
1001RCC0.0157.7+b46.9+c
2002Neuroendocrine0.0153.912.4
1004Prostate0.042.3+d19.9+d
1005RCC0.041.4+d1.4+d
1012RCC0.042.811.6
2004Head and neck0.0410.421.0
4005Melanoma0.045.012.4
1007RCC0.083.016.1
3001Melanoma0.0829.0+e29.0+c
4001Melanoma0.089.535.4+c
  • aContribution of poststudy therapy, if any, not assessed.

  • bNo recent tumor assessment available.

  • cAlive as of last report.

  • dLost to follow-up.

  • eNo evidence of disease as of last report.